Discontinued in 2013: Oncology drugs

Expert Opinion on Investigational Drugs

Volumn 24, Issue 1, 2015, Pages 95-110

  Williams, Robert ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

4SC 203; Allovectin 7; ANX 514; ASG 5ME; ASP 9603; AZD 8330; BMS 582644; Brivanib alaninate; Cilengitide; CP 4055; CS 7017; E 6201; Efatutazone; Elacytarabine; EMD 121974; Enzastaurin; Fedratinib; IMC RON8; Imgatuzumab; Iniparib; IPI 504; KHK 2866; KW 2450; Litronesib; LY 2334737; LY 2523355; LY 2603618; LY 3007113; LY 317615; MEDI 575; Narnatumab; OSI 027; Palifosfamide; Parsatuzumab; PF 4605412; PR1 vaccine; PWT 33597; Rabusertib; Retaspimycin; RG 7112; RG 7160; RG 7414; RG 7420; SAR 240550; SAR 302503; SAR 402674; Sepantronium bromide; SGN 75; TAK 441; TAK 448; TAK 960; Talactoferrin ; TAS 266; Tovetumab; Velimogene aliplasmid; Vorsetuzumab mafodotin; YM 155; ZIO 201

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR MARKER;

DRUG RESEARCH; HUMAN; ONCOLOGY; OUTCOME ASSESSMENT; PATIENT SELECTION; PHARMACODYNAMICS; REVIEW;

EID: 84916912044     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.971154     Document Type: Review

References (17)

1. Williams RJ. Discontinued drugs in 2012: oncology drugs. Expert Opin Investig Drugs 2013;22(12):1627-44
2. Borden C and Dowlati A. Phase I trials of targeted anticancer drugs: A need to refoucus. Nature Rev Drug Discov 2012;11:889-90
3. Cook D, Brown D, Alexander R, et al. Lessons learned from the fate of AstraZenecas drug pipeline: A fivedimensional framework. Nature Rev Drug Discov 2014;6):419-31
4. Morgan P, Van Der Graff P, Arrowsmith J, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Disc Today 2012;17(9-10):419-24
5. Cohen RB, Aamdal S, Nyakas M, et al. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur J Cancer 2013;49(7):1521-5129
6. Mateo J, Ong M, Tan DSP, et al. Appraising iniparib, the PARP inhibitor that never was-what must we learn? Nat Rev Clin Oncol 2013;10(12):688-96
7. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R &D productivity: the pharmaceutical industrys grand challenge. Nature Rev Drug Discov 2010;3):203-14
8. Arrowsmith A and Miller P. Phase II and phase III attrition rates 2011-2012. Nature Rev Drug Discov 2013;12(8):569
9. DiMasi JA. Causes of clinical failures vary widely by therapeutic class, phase of study. Tufts Impact Report 2013;15:5
10. Bradley E. Incorporating biomarkers into clinical trial designs: points to consider. Nature Biotech 2012;7):596-9
11. Available from: https://clinicaltrials.gov
12. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nature Rev Drug Disc 2004;3(8):711-15
13. Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. Nature Biotech 2014;32(1):40-51
14. Rubin EH, Gilland DG. Drug development and clinical trials - the path to an approved cancer drug. Nat Rev Clin Oncol 2012;9(4):215-22
15. Available from: www.scripintelligence.com/home/Is-the-cost-of-Anticancertherapy-justified-350983
16. Ringel M, Tollman P, Hersch G, Schulze U. Does size matter in R &D productivity? If not, what does? Nature Rev Drug Discov 2013;12(12):901-2
17. Pharma 2020 - From vision to decision. Available from: www.pwc.co.uk/pharmaceuticals-life-sciences/publications/from-vision-to-decision-pharma-2020.jhtml